Overview of the Legal Situation Concerning Altimmune, Inc.
Recently, Altimmune, Inc. has found itself in the center of a class action securities lawsuit. Levi & Korsinsky, LLP has taken the initiative to inform investors affected by this lawsuit. In particular, the legal action is grounded in claims regarding alleged securities fraud that impacted shareholders from August 10, 2023, through June 25, 2025.
Understanding the Class Action Lawsuit
The crux of the lawsuit revolves around the recovery of losses incurred by individuals who invested in Altimmune during the mentioned timeframe. Class action lawsuits like this serve as a vehicle for investors to reclaim some of their losses collectively, making legal representation both accessible and effective.
Recent Developments Affecting Altimmune Investors
On June 26, 2025, the company issued a press release regarding the results from the IMPACT Phase 2b MASH trial of Pemvidutide. This trial aimed to treat conditions associated with MASH, but the results were underwhelming. Despite having outlined positive expectations in prior communications, the results indicated a failure to achieve the primary endpoint for statistical significance concerning fibrosis reduction.
The Stock Price Reaction
Following this announcement, Altimmune's stock price experienced a troubling drop. On June 25, 2025, shares closed at $7.71, only to plunge to $3.61 the next day, marking a drastic decline of 53.2%. Such a significant decrease in stock value raises concerns among shareholders, prompting legal scrutiny.
Next Steps for Affected Investors
For investors who feel they have suffered losses due to the situations surrounding Altimmune, it’s crucial to act promptly. Those affected by the securities allegations have until October 6, 2025, to step forward and request the court to appoint them as lead plaintiffs. Even if investors choose not to take on the lead plaintiff role, they can still participate in any potential recovery efforts.
No Financial Burden on Investors
One of the significant benefits of participating in a class action lawsuit is that investors can reclaim losses without incurring out-of-pocket costs or fees. This means there’s no financial obligation to participate, ensuring that victims of alleged securities fraud can seek justice without worrying about additional financial strains.
Why Choose Levi & Korsinsky for Legal Representation?
Over the past two decades, Levi & Korsinsky has established a commendable track record representing aggrieved shareholders. They have successfully secured settlements amounting to hundreds of millions of dollars for their clients, showcasing their expertise in complex securities litigation. Their firm includes over 70 professionals dedicated to ensuring every client's interests are prioritized.
Contact Information for Interested Parties
Investors interested in discussing their rights or seeking guidance can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky, LLP. You can contact him via email or telephone at (212) 363-7500 to understand your options and the next steps.
Frequently Asked Questions
What is the lawsuit against Altimmune about?
The lawsuit centers around allegations of securities fraud impacting investors between August 10, 2023, and June 25, 2025.
How has the stock price of Altimmune reacted recently?
Altimmune's stock price fell dramatically from $7.71 to $3.61 following disappointing trial results, marking a 53.2% drop.
What are the next steps for investors who lost money?
Investors have until October 6, 2025, to request appointment as lead plaintiffs and pursue potential recovery.
Is there a cost to join the class action lawsuit?
No, if you are a class member, there are no out-of-pocket costs associated with participating in the lawsuit.
Why should investors choose Levi & Korsinsky?
Levi & Korsinsky has a proven history of success securing significant settlements for shareholders and offers expertise in securities litigation.
